-
Tislelizumab Earns European Approval in Non–Small Cell Lung Cancer
23 Apr 2024 17:43 GMT
… to a press release from developers BeiGene, Ltd.1
Specifically, the … for tislelizumab as treatment for non-small cell lung cancer. News release. BeiGene … non–small-cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol …
-
Research Progress of Baihe Gujin Decoction in the Treatment of Lung Cancer
23 Apr 2024 17:30 GMT
… formation and finally develops into lung cancer.15 Deficiency of … used as a routine medication for the prevention … emerging various new drugs for the treatment of lung cancer, chemotherapy still … in the treatment of lung cancer. Asia-Pacific Tradit Med. 2016; …
-
FDA Approves Immunotherapy That Can Spare Bladder Cancer Patients From Radical Surgery
23 Apr 2024 20:54 GMT
… FDA has approved ImmunityBio’s therapy, Anktivo, for the treatment … include checkpoint inhibitors, drugs that block a protein … therapy.
Anktiva was initially developed by Altor BioScience, … clinical trials for Anktiva are underway or planned in lung cancer, …
-
Pillar Biosciences oncoReveal™ CDx pan-cancer solid tumor IVD now FDA approved for general tumor profiling on the Illumina MiSeq™ Dx System
23 Apr 2024 20:18 GMT
… in Decision Medicine™, which develops and distributes next-generation … Food and Drug Administration (FDA) has approved the company… in non-small cell lung cancer (NSCLC) and colorectal cancer … companies to help improve treatment decisions and deliver outcomes …
-
Lung Cancer Cells Switch Oncogenic Drivers
23 Apr 2024 13:08 GMT
… lung cancer biologist at Weill Cornell Medicine, and his colleagues developed … different lung cancer types. “I didn’t really develop anything … in patients to guide treatment decisions. However, he … given the heterogeneity of lung cancer.
Watanabe believes that …
-
Lantern Pharma cleared to expand lung cancer treatment trial
23 Apr 2024 11:50 GMT
… small cell lung cancer (NSCLC).
The multicentre, open-label trial aims to … evaluation and development stages.
In Japan, the trial will be … represents a promising new treatment option for never-smokers … -300 is being developed as a treatment for relapsed and …
-
Krystal Biotech doses first subject in lung cancer drug trial
23 Apr 2024 11:50 GMT
US-based biotechnology company Krystal Biotech has dosed the first subject in the Phase I KYANITE-1 clinical trial for its inhaled oncology candidate, KB707, aimed at treating patients with locally advanced or metastatic solid lung tumours.
A modified HSV- …
-
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
23 Apr 2024 10:17 GMT
… tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across three … had positive readouts. Through these trials, tislelizumab has demonstrated its potential … third parties to conduct drug development, manufacturing, commercialization, and other …
-
Visiting Speaker to Discuss Impacts of Treatment and Tumor on Wasting During Lung Cancer
23 Apr 2024 07:35 GMT
… Treatment and Tumor Effects to Provoke Muscle and Adipose Wasting During Lung Cancer … structural and functional adaptations in lung cancer patients published in the prestigious … Muscle and studies working to develop better pre-clinical models of …
-
AFNT-211 by Affini-T Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
23 Apr 2024 03:29 GMT
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role …